Gutierrez Wealth Advisory LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Gutierrez Wealth Advisory LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,219 shares of the medical research company's stock, valued at approximately $318,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Legacy Investment Solutions LLC purchased a new stake in Amgen in the third quarter worth about $29,000. Centricity Wealth Management LLC bought a new stake in shares of Amgen in the 4th quarter valued at about $25,000. Synergy Investment Management LLC purchased a new stake in shares of Amgen in the 4th quarter worth approximately $34,000. Atala Financial Inc bought a new position in shares of Amgen during the fourth quarter valued at approximately $34,000. Finally, Heck Capital Advisors LLC purchased a new position in Amgen during the fourth quarter valued at approximately $36,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

Shares of AMGN stock traded down $7.52 during mid-day trading on Tuesday, hitting $306.86. 2,564,825 shares of the stock were exchanged, compared to its average volume of 2,551,876. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The firm has a fifty day moving average of $298.13 and a 200 day moving average of $298.50. The company has a market cap of $164.85 billion, a PE ratio of 40.64, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53.

Remove Ads

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.10%. The ex-dividend date is Friday, May 16th. Amgen's payout ratio is 126.09%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of analyst reports. Truist Financial lowered their target price on Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a report on Wednesday, January 8th. Bank of America raised their price objective on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. StockNews.com downgraded shares of Amgen from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Leerink Partners lowered their price target on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $324.00 price objective on shares of Amgen in a research note on Friday, January 24th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $314.04.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now directly owns 28,987 shares of the company's stock, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.